| Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097] | Technology appraisal guidance |
| Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097] | Technology appraisal guidance |
| Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830] | Technology appraisal guidance |
| Edaravone for treating amyotrophic lateral sclerosis [TSID11869] | Technology appraisal guidance |
| Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046] | Technology appraisal guidance |
| Elamipretide for treating Barth syndrome in people of any age [ID6545] | Technology appraisal guidance |
| Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847] | Technology appraisal guidance |
| Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359] | Technology appraisal guidance |
| Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544] | Technology appraisal guidance |
| Elinzanetant for Vasomotor symptoms [ID6544] | Technology appraisal guidance |
| Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464] | Technology appraisal guidance |
| Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [TSID12180] | Technology appraisal guidance |
| Eneboparatide for treating chronic hypoparathyroidism [ID6532] | Technology appraisal guidance |
| Eneboparatide for treating chronic hypoparathyroidism [TSID12145] | Technology appraisal guidance |
| Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301] | Technology appraisal guidance |
| Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [TSID12146] | Technology appraisal guidance |
| Ensitrelvir for treating COVID 19 [ID6231] | Technology appraisal guidance |
| Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463] | Technology appraisal guidance |
| Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID12197] | Technology appraisal guidance |
| Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [TSID12015] | Technology appraisal guidance |
| Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037] | Technology appraisal guidance |
| Etripamil for treating paroxysmal supraventricular tachycardia [TSID12184] | Technology appraisal guidance |
| Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827] | Technology appraisal guidance |
| Extra-vascular implantable cardioverter defibrillator (EVICD) for people with a defibrillator | Interventional procedures guidance |
| Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278] | Technology appraisal guidance |